The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Mechanisms of aromatase inhibitor resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., Brown, G. D., Gojis, O., Ellis, I. O., Green, A. R., et al. (2012) · Nature · doi:10.1038/nature10730 · Cited by 2,173
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., Pilotti, S., Pierotti, M. A., & Daidone, M. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0626 · Cited by 1,723
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72384-7 · Cited by 1,608
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer
Stark, R. (2012) · Lecture Notes in Computer Science · doi:10.1007/978-3-642-29627-7_30 · Cited by 1,403
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.008 · Cited by 1,384
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353
Cancer to bone: a fatal attraction
Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3055 · Cited by 1,285
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
Self-citationGoss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Dynamic FoxO transcription factors
Huang, H., & Tindall, D. J. (2007) · Journal of Cell Science · doi:10.1242/jcs.001222 · Cited by 1,113
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Shah, S. P., Morin, R. D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., et al. (2009) · Nature · doi:10.1038/nature08489 · Cited by 1,069
Whole-genome analysis informs breast cancer response to aromatase inhibition
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., et al. (2012) · Nature · doi:10.1038/nature11143 · Cited by 1,023
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C. R. M., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420801 · Cited by 923
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
Self-citationKaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404037 · Cited by 749
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Self-citationTan, W., Zhang, W., Strasner, A., Grivennikov, S., Cheng, J. Q., Hoffman, R. M., & Karin, M. (2011) · Nature · doi:10.1038/nature09707 · Cited by 647
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Self-citationDynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., Gelmon, K., Chia, S., Mar, C., Wan, A., et al. (2015) · Nature · doi:10.1038/nature13952 · Cited by 598
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
Baratelli, F., Lin, Y., Zhu, L., Yang, S.-C., Heuzé-Vourc’h, N., Zeng, G., Reckamp, K., Dohadwala, M., Sharma, S., & Dubinett, S. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1483 · Cited by 573
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J., DeSchryver, K., Allred, D. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6950 · Cited by 551
Self-citationRegulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Harrison, H., Farnie, G., Howell, S. J., Rock, R. E., Stylianou, S., Brennan, K. R., Bundred, N. J., & Clarke, R. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1681 · Cited by 543
Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling
Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523
Massarweh, S., Osborne, C. K., Creighton, C. J., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., & Schiff, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2707 · Cited by 488
Ottaviano, Y. L., Issa, J. J., Parl, F. F., Smith, H. S., Baylin, S. B., & Davidson, N. E. (1994) · PubMed · Cited by 481
Diel, I. J., Kaufmann, M., Costa, S. D., Holle, R., von Minckwitz, G., Solomayer, E. F., Kaul, S., & Bastert, G. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.22.1652 · Cited by 477
Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer
Treilleux, I., Blay, J.-Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J.-P., Bremond, A., Goddard, S., Pin, J.-J., Barthelemy-Dubois, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0684 · Cited by 460
AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor
Font de Mora, J., & Brown, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5041-5047.2000 · Cited by 432
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Garattini, S. K., Shore, P. A., & August, T. (1962) · Academic Press eBooks · Cited by 409
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kalinsky, K., Jacks, L. M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D., Gerald, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401
Variant human breast tumor estrogen receptor with constitutive transcriptional activity.
Fuqua, S. A. W., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O’Malley, B. W., & McGuire, W. L. (1991) · PubMed · Cited by 394
Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 393
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Holst, F., Stahl, P. R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K., Jänicke, F., et al. (2007) · Nature Genetics · doi:10.1038/ng2006 · Cited by 375
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 366
Plasma membrane estrogen receptors
Levin, E. R. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.06.009 · Cited by 365
Targeting Breast Cancer Stem Cells
Liu, S., & Wicha, M. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 356
Song, R. X., Barnes, C. J., Zhang, Z., Bao, Y., Kumar, R., & Santen, R. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308334100 · Cited by 349
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer
Robinson, D. R., Kalyana-Sundaram, S., Wu, Y.-M., Shankar, S., Cao, X., Ateeq, B., Asangani, I. A., Iyer, M., Maher, C. A., Grasso, C. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2580 · Cited by 340
Widschwendter, M., Siegmund, K. D., Müller, H. M., Fiegl, H., Marth, C., Müller-Holzner, E., Jones, P. A., & Laird, P. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3852 · Cited by 324
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt337 · Cited by 321
Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
Martin, L.-A., Farmer, I., Johnston, S. R. D., Ali, S., Marshall, C., & Dowsett, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305226200 · Cited by 295
Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 291
Ellis, M. J., Gao, F., Dehdashti, F., Jeffe, D. B., Marcom, P. K., Carey, L. A., Dickler, M. N., Silverman, P., Fleming, G. F., Kommareddy, A., et al. (2009) · JAMA · doi:10.1001/jama.2009.1204 · Cited by 287
Self-citationMauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj357 · Cited by 286
Roodi, N., Bailey, L. R., Kao, W.-Y., Verrier, C. S., Yee, C. J., Dupont, W. D., & Parl, F. F. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.6.446 · Cited by 266
Hiscox, S., Jiang, W. G., Obermeier, K., Taylor, K., Morgan, L., Burmi, R., Barrow, D., & Nicholson, R. I. (2006) · International Journal of Cancer · doi:10.1002/ijc.21355 · Cited by 260
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Arpino, G., Green, S. J., Allred, D. C., Lew, D., Martino, S., Osborne, C. K., & Elledge, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0110 · Cited by 255
(2023) · Advances in Pharmacology · doi:10.1016/s1054-3589(23)00038-8 · Cited by 251
Creighton, C. J., Hilger, A. M., Murthy, S., Rae, J. M., Chinnaiyan, A. M., & El-Ashry, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4363 · Cited by 243
Chen, D., Washbrook, E., Sarwar, N., Bates, G. J., Pace, P. E., Thirunuvakkarasu, V., Taylor, J., Epstein, R. J., Fuller-Pace, F. V., Egly, J.-M., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205420 · Cited by 236
Yang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., & Davidson, N. E. (2000) · PubMed · Cited by 228
Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells
Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., & El-Ashry, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.8.0678 · Cited by 226
Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218
Self-citationEngelmann, K., Shen, H., & Finn, O. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2249 · Cited by 216
Selective targeting of radiation-resistant tumor-initiating cells
Zhang, M., Atkinson, R. L., & Rosen, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910179107 · Cited by 216
Carcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells
Polanska, U. M., & Orimo, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24347 · Cited by 208
Tran, D. D., Corsa, C. A. S., Biswas, H., Aft, R. L., & Longmore, G. D. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0371 · Cited by 200
Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer
Hopp, T. A., Weiss, H. L., Parra, I. S., Cui, Y., Osborne, C. K., & Fuqua, S. A. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1114 · Cited by 197
Fan, P., Wang, J., Santen, R. J., & Yue, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1020 · Cited by 188
Schwartzberg, L. S., Franco, S. X., Florance, A., O'Rourke, L., Maltzman, J., & Johnston, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0240 · Cited by 188
PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Cizkova, M., Susini, A., Vacher, S., Cizeron-Clairac, G., Andrieu, C., Driouch, K., Fourme, E., Lidereau, R., & Bièche, I. (2012) · Breast Cancer Research · doi:10.1186/bcr3113 · Cited by 186
Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., Lin, L., & Ellis, M. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2833 · Cited by 184
Self-citationOsborne, C. K., Neven, P., Dirix, L. Y., Mackey, J. R., Robert, J., Underhill, C., Schiff, R., Gutierrez, C., Migliaccio, I., Anagnostou, V. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1869 · Cited by 179
Veeraraghavan, J., Tan, Y., Cao, X.-X., Kim, J. A., Wang, X., Chamness, G. C., Maiti, S. N., Cooper, L. J. N., Edwards, D. P., Contreras, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5577 · Cited by 176
Targeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists
WANG, S. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.015 · Cited by 175
Martinez-Outschoorn, U. E., Goldberg, A. F., Lin, Z., Ko, Y.-H., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R. G., Howell, A., Sotgia, F., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.10.17780 · Cited by 174
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Emens, L. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.147 · Cited by 172
Reid, G., Métivier, R., Lin, C., Denger, S., Ibberson, D., Ivacevic, T., Brand, H., Beneš, V., Liu, E. T., & Gannon, F. (2005) · Oncogene · doi:10.1038/sj.onc.1208662 · Cited by 172
Guo, S., & Sonenshein, G. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8681-8690.2004 · Cited by 168
Lupien, M., Meyer, C. A., Bailey, S. T., Eeckhoute, J., Cook, J., Westerling, T., Zhang, X., Carroll, J. S., Rhodes, D. R., Liu, X. S., et al. (2010) · Genes & Development · doi:10.1101/gad.1944810 · Cited by 165
Death Receptor Agonists as a Targeted Therapy for Cancer
Wiezorek, J., Holland, P., & Graves, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1692 · Cited by 160
Generali, D., Bates, G., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1507 · Cited by 160
Dunbier, A. K., Ghazoui, Z. F., Anderson, H., Salter, J., Nerurkar, A. Y., Osin, P., A’Hern, R., Miller, W. R., Smith, I. E., & Dowsett, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1000 · Cited by 159
Sabnis, G. J., Goloubeva, O., Chumsri, S., Nguyen, N., Sukumar, S., & Brodie, A. M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2458 · Cited by 158
Kühnle, M., Egger, M. E., Müller, C., Mahringer, A., Bernhardt, G., Fricker, G., König, B., & Buschauer, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8013822 · Cited by 158
Cancer Stem Cells as Mediators of Treatment Resistance in Brain Tumors: Status and Controversies
Sakariassen, P. Ø., Immervoll, H., & Chekenya, M. (2007) · Neoplasia · doi:10.1593/neo.07658 · Cited by 158
Sahla, M. E., Simony-Lafontaine, J., Kramar, A., Lavaill, R., Mollévi, C., Warner, M. N., Gustafsson, J.-Α., & Rochefort, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0389 · Cited by 158
Marcom, P. K., Isaacs, C. J., Harris, L. N., Wong, Z. W., Kommareddy, A., Novielli, N., Mann, G., Tao, Y., & Ellis, M. J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9307-8 · Cited by 154
Self-citationFox, E. M., Miller, T. W., Balko, J. M., Kuba, M. G., Sanchez, V. M., Smith, R. A., Liu, S., Gonzalez-Angulo, A. M., Mills, G. B., Ye, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1295 · Cited by 154
Rhodes, L. V., Short, S. P., Neel, N. F., Salvo, V. A., Zhu, Y., Elliott, S., Wei, Y., Yu, D., Sun, M., Muir, S. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3185 · Cited by 154
Kristensen, V. N., Vaske, C. J., Ursini‐Siegel, J., Loo, P. V., Nord, S., Sachidanandam, R., Sørlie, T., Wärnberg, F., Haakensen, V. D., Helland, Å., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108781108 · Cited by 153
Keen, J. C., Lan, Y., Mack, K. M., Pettit, C., Smith, D., Sharma, D., & Davidson, N. E. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1026146524737 · Cited by 151
Targeting apoptosis pathways in cancer stem cells
Signore, M., Ricci‐Vitiani, L., & Maria, R. D. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.013 · Cited by 141
Targeting tumor–stromal interactions in bone metastasis
Esposito, M., & Kang, Y. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.006 · Cited by 141
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
Lin, N., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0946 · Cited by 137
Okuhira, K., Demizu, Y., Hattori, T., Ohoka, N., Shibata, N., Nishimaki‐Mogami, T., Okuda, H., Kurihara, M., & Naito, M. (2013) · Cancer Science · doi:10.1111/cas.12272 · Cited by 133
Finn, R., Crown, J. P., Láng, I., Boér, K., Bondarenko, I., Kulyk, S. V., Ettl, J., Patel, R., Pintér, T., Schmidt, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s1-6 · Cited by 128
Bayliss, J. M., Hilger, A., Vishnu, P., Diehl, K. M., & El‐Ashry, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0587 · Cited by 122
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence
Rhodes, L. V., Muir, S. E., Elliott, S. G., Guillot, L. M., Antoon, J. W., Penfornis, P., Tilghman, S. L., Salvo, V. A., Fonseca, J. P., Lacey, M. R., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0458-2 · Cited by 110
The impact of tumor stroma on drug response in breast cancer
Dittmer, J., & Leyh, B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.006 · Cited by 109
Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch
Haughian, J. M., Pinto, M. P., Harrell, J. C., Bliesner, B., Joensuu, K. M., Dye, W. W., Sartorius, C. A., Tan, A. C., Heikkilä, P., Perou, C. M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106509108 · Cited by 100
Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters
Kiyotani, K., Mushiroda, T., Nakamura, Y., & Zembutsu, H. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-084 · Cited by 100
Jeng, M., Yue, W., Eischeid, A. C., Wang, J., & Santen, R. J. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006406030612 · Cited by 99
Harrison, H., Simões, B. M., Rogerson, L., Howell, S. J., Landberg, G., & Clarke, R. B. (2013) · Breast Cancer Research · doi:10.1186/bcr3396 · Cited by 98
AKT Alters Genome-Wide Estrogen Receptor α Binding and Impacts Estrogen Signaling in Breast Cancer
Bhat‐Nakshatri, P., Wang, G., Appaiah, H. N., Luktuke, N., Carroll, J. S., Geistlinger, T., Brown, M. A., Badve, S., Liu, Y., & Nakshatri, H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00799-08 · Cited by 89
Burstein, H. J., Cirrincione, C., Barry, W. T., Chew, H. K., Tolaney, S. M., Lake, D. E., Ma, C. X., Blackwell, K., Winer, E. P., & Hudis, C. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7941 · Cited by 89
Self-citationRole of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer
Lan, Y., Yang, X., & Davidson, N. E. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1011308707512 · Cited by 85
Rajbhandari, P., Finn, G., Solodin, N. M., Singarapu, K. K., Sahu, S. C., Markley, J. L., Kadunc, K., Miner, S. J., Kariagina, A., Haslam, S. Z., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06073-11 · Cited by 85
ESR1 gene amplification in breast cancer: a common phenomenon?
Reis-Filho, J. S., Drury, S., Lambros, M. B. K., Marchiò, C., Johnson, N., Natrajan, R., Salter, J., Levey, P. M., Fletcher, O., Peto, J., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-809b · Cited by 85
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
Ellis, M. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-20 · Cited by 84
Self-citationHirokawa, Y., Arnold, M., Nakajima, H., Zalcberg, J. R., & Maruta, H. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.9.1911 · Cited by 81
Madeira, M., Mattar, A. P. L., Logullo, Â. F., Soares, F. A., & Gebrim, L. H. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-425 · Cited by 79
Tomita, S., Zhang, Z., Nakano, M., Ibusuki, M., Kawazoe, T., Yamamoto, Y., & Iwase, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01145.x · Cited by 78
Johnston, S. R. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.889s.11.2 · Cited by 75
Zhou, Q. Y., Shaw, P. G., & Davidson, N. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0148-5 · Cited by 75
Oncogenic K-ras in Mouse Models of Myeloproliferative Disease and Acute Myeloid Leukemia
Chan, I. T., & Gilliland, D. G. (2004) · Cell Cycle · doi:10.4161/cc.3.5.827 · Cited by 75
Crawford, A. C., Riggins, R. B., Shajahan‐Haq, A. N., Zwart, A. L., & Clarke, R. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008604 · Cited by 71
Shi, X., Miao, S., Wu, Y., Zhang, W., Zhang, X., Ma, H.-Z., Hai-li, X., Feng, J., Wen, A., & Li, Y. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815655 · Cited by 69
Stephen, R. L., Shaw, L. E., Larsen, C., Corcoran, D. L., & Darbre, P. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105892200 · Cited by 67
ESR1 gene amplification in breast cancer: a common phenomenon?
Brown, L. A., Hoog, J., Chin, S., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-806 · Cited by 66
Hedgehog Signaling: Networking to Nurture a Promalignant Tumor Microenvironment
Harris, L. G., Samant, R. S., & Shevde, L. A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0175 · Cited by 66
Hardt, O., Wild, S., Oerlecke, I., Hofmann, K., Luo, S., Wiencek, Y., Kantelhardt, E., Vess, C., Smith, G. P., Schroth, G. P., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.010 · Cited by 64
Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer
Tchou, J. C., & Conejo-Garcia, J. R. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00003-8 · Cited by 64
Hiscox, S., Jordan, N., Jiang, W. G., Harper, M. E., McClelland, R. A., Smith, C. R., & Nicholson, R. I. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01270 · Cited by 62
The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm
López‐Tarruella, S., & Schiff, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1399 · Cited by 61
Schwartz‐Roberts, J. L., Shajahan‐Haq, A. N., Cook, K. L., Wärri, A. M., Abu-Asab, M. S., & Clarke, R. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0617 · Cited by 55
Ooi, A., Inokuchi, M., Harada, S., Inazawa, J., Tajiri, R., Kitamura, S., Ikeda, H., Kawashima, H., & Dobashi, Y. (2011) · The Journal of Pathology · doi:10.1002/path.3974 · Cited by 52
RNA-Seq Mapping and Detection of Gene Fusions with a Suffix Array Algorithm
Sakarya, O., Breu, H., Radovich, M., Chen, Y., Wang, Y., Bárbácioru, C., Utiramerur, S., Whitley, P., Brockman, J. P., Vatta, P., et al. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002464 · Cited by 49
Ben‐Aharon, I., Vidal, L., Rizel, S., Yerushalmi, R., Shpilberg, O., Sulkes, A., & Stemmer, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070044 · Cited by 47
Roop, R. P., & Ma, C. X. (2012) · Future Oncology · doi:10.2217/fon.12.8 · Cited by 41
Self-citationUse of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
Gonçalves, R., Ma, C. X., Luo, J. R., Suman, V. J., & Ellis, M. J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.21 · Cited by 40
Self-citationTargeting Truncated Retinoid X Receptor-α by CF31 Induces TNF-α–Dependent Apoptosis
Wang, G., Jiang, F., Duan, Y., Zeng, Z., Chen, F., Dai, Y., Chen, J., Liu, J., Liu, J., Zhou, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2038 · Cited by 39
Ghazoui, Z. F., Buffa, F. M., Dunbier, A. K., Anderson, H., Dexter, T., DETRE, S. I., Salter, J., Smith, I. E., Harris, A. L., & Dowsett, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1704 · Cited by 36
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-dependent Manner
Stanculescu, A., Bembinster, L. A., Borgen, K. R., Bergamaschi, A., Wiley, E. L., & Frasor, J. M. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0018-6 · Cited by 34
Juric, D., Argilés, G., Burris, H., Gonzalez-Angulo, A., Saura, C., Quadt, C., Douglas, M., Demanse, D., Buck, S., & Baselga, J. M. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p6-10-07 · Cited by 31
Borley, A., Hiscox, S., Gee, J. M. W., Smith, C. R., Shaw, V. E., Barrett-Lee, P. J., & Nicholson, R. I. (2008) · Breast Cancer Research · doi:10.1186/bcr2206 · Cited by 31
Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer
Robertson, J. F. R. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85032-9 · Cited by 28
Robertson, J. F. R., Llombart‐Cussac, A., Feltl, D., Dewar, J. A., Jasiówka, M., Hewson, N., Rukazenkov, Y., & Ellis, M. J. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s6-04 · Cited by 25
Self-citationMa, Y., Ambannavar, R., Stephans, J. C., Jeong, J., Rossi, A. D., Liu, M., Friedman, A. J., Londry, J. J., Abramson, R. G., Beasley, E. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094202 · Cited by 24
Absence of ESR1 amplification in a series of breast cancers
Adélaı̈de, J., Finetti, P., Charafe‐Jauffret, E., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23786 · Cited by 23
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use
Zanotti, L., Bottini, A., Rossi, C., Generali, D., & Cappelletti, M. R. (2014) · Tumor Biology · doi:10.1007/s13277-014-2366-2 · Cited by 21
Paul, D., Vukelja, S., Holmes, F., Blum, J. L., Kj, M., Ar, K., Lindquist, D., Osborne, C., Sanchez, I., Goldschmidt, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-s3-07 · Cited by 19
Moelans, C. B., Holst, F., Hellwinkel, O., Simon, R., & van Diest, P. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084189 · Cited by 19
Piccart, M. J., Hortobágyi, G. N., Campone, M., Pritchard, K. I., Noguchi, S., Rugo, H. S., Gnant, M., Feng, W., Taran, T., & Baselga, J. M. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)00221-4 · Cited by 16
Molecular Pathways: Extracting Medical Knowledge from High-Throughput Genomic Data
Goldstein, T. C., Paull, E., Ellis, M. J., & Stuart, J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2093 · Cited by 14
Self-citationESR1 amplification in breast cancer: controversy resolved?
Albertson, D. G. (2012) · The Journal of Pathology · doi:10.1002/path.3999 · Cited by 8
Research works printed but not linked: 15
- Ellis, M. J. et al. Z1031B neoadjuvant aromatase inhibitor trial: a phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%. Cancer Res. 72, PD07-01 (2012). · doi:10.1158/0008-5472.sabcs12-pd07-01
- Ellis, M. J. et al. Tumor Ki67 proliferation index within 4 weeks of initiating neoadjuvant endocrine therapy for early identification of non-responders. Cancer Res. 69, 78 (2009). · doi:10.1158/0008-5472.sabcs-09-78
- Goncalves, R. et al. A Ki67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. J. Pharmacogenomics Pharmacoproteomics 5, 5 (2014).
- Fan, P. et al. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur. J. Cancer 50, 457–468 (2014). · doi:10.1016/j.ejca.2013.10.001
- Vincent-Salomon, A., Raynal, V., Lucchesi, C., Gruel, N. & Delattre, O. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 809 (2008). · doi:10.1038/ng0708-809a
- Horlings, H. M. et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 807–808 (2008). · doi:10.1038/ng0708-807
- Holst, F. et al. On the evidence for ESR1 amplification in breast cancer. Nature Rev. Cancer 12, 149 (2012). · doi:10.1038/nrc3093-c3
- Moelans, C. B. et al. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal. Cell. Pathol. (Amst.) 33, 13–18 (2010). · doi:10.1155/2010/619180
- Kaufman, P. A. et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res. 70, S1–S4 (2010). · doi:10.1158/0008-5472.can-09-4246
- Hortobagyi, G. N. et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J. Clin. Oncol. 31, LBA509 (2013). · doi:10.1200/jco.2013.31.18_suppl.lba509
- Giacinti, L. et al. Scriptaid effects on breast cancer cell lines. J. Cell. Physiol. 227, 3426–3433 (2012). · doi:10.1002/jcp.24043
- Marks, P. A. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 3, 534–535 (2004). · doi:10.4161/cc.3.5.824
- Bianchini, G. et al. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. J. Clin. Oncol. 30, 545 (2012). · doi:10.1200/jco.2012.30.4_suppl.545
- Piccart, M. et al. Assessment of genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer from the BOLERO-2 trial by next-generation sequencing. Ann. Oncol. 24 (Suppl. 3), 25–26 (2013). · doi:10.1093/annonc/mdt083.3
- Adelson, K. B., Raptis, G., Sparano, J. & Germain, D. Randomized phase II study of fulvestrant versus fulvestrant plus bortezomib in postmenopausal women with estrogen receptor (ER) positive, aromatase-inhibitor (AI) resistant metastatic breast cancer (MBC): New York Cancer Consortium trial P8457. Cancer Res. 71, OT3-01-01 (2014). · doi:10.1158/0008-5472.sabcs11-ot3-01-01
Cited by
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 565
Metadata
- Authors
- Ma, C. X., Reinert, T., Chmielewska, I., & Ellis, M. J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-04-24
- Volume
- 15
- Issue
- 5
- Pages
- 261-275
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1992533338
- Cited by
- 407
- References
- 174
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.